BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-1.31%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$15.3B
AUM Growth
+$15.3B
(-13%)
Cap. Flow
-$363M
Cap. Flow
% of AUM
-2.38%
Top 10 Holdings %
Top 10 Hldgs %
84.69%
Holding
129
New
12
Increased
7
Reduced
17
Closed
13
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$76.6M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
$47.5M |
| 3 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$26.5M |
| 4 |
IDEAYA Biosciences
IDYA
|
$24.9M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$19.6M |
Top Sells
| 1 |
argenx
ARGX
|
$296M |
| 2 |
Legend Biotech
LEGN
|
$47.1M |
| 3 |
Insmed
INSM
|
$46M |
| 4 |
Krystal Biotech
KRYS
|
$26.9M |
| 5 |
Pacific Biosciences
PACB
|
$25.1M |
Sector Composition
| 1 | Healthcare | 98.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Nurix Therapeutics
NRIX
$723M
| $50.6M | 0.33% |
3,882,125
| – | – |
|
|
KDNY
27
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $49.8M | 0.33% |
2,534,102
| – | – |
|
|
VERV
28
DELISTED
Verve Therapeutics
VERV
| $48.7M | 0.32% |
1,416,530
| – | – |
|
29
Immatics
IMTX
$662M
| $44.2M | 0.29% |
4,423,731
| – | – |
|
|
FMTX
30
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $37.6M | 0.25% |
1,886,760
-138,116
| -7% | -$2.76M |
|
31
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $35.9M | 0.24% |
2,799,577
| – | – |
|
32
Heron Therapeutics
HRTX
$204M
| $34.3M | 0.22% |
8,131,678
| – | – |
|
|
JBIO
33
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $32.8M | 0.21% |
56,559
-2,584
| -4% | -$1.5M |
|
|
TSVT
34
DELISTED
2seventy bio
TSVT
| $30M | 0.2% |
2,062,744
| – | – |
|
|
35
Krystal Biotech
KRYS
$4.35B
| $29.4M | 0.19% |
422,185
-385,550
| -48% | -$26.9M |
|
36
Xenon Pharmaceuticals
XENE
$2.99B
| $27.1M | 0.18% |
751,639
| – | – |
|
|
CINC
37
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $26.5M | 0.17% |
+807,212
| New | +$26.5M |
|
|
DBVT
38
DBV Technologies
DBVT
$249M
| $25.9M | 0.17% |
1,461,426
| – | – |
|
|
39
IDEAYA Biosciences
IDYA
$2.26B
| $24.9M | 0.16% |
+1,668,355
| New | +$24.9M |
|
40
Design Therapeutics
DSGN
$339M
| $24M | 0.16% |
1,436,636
| – | – |
|
41
Verastem
VSTM
$585M
| $22.9M | 0.15% |
2,249,075
| – | – |
|
42
Altimmune
ALT
$325M
| $22.6M | 0.15% |
1,769,681
-305,722
| -15% | -$3.9M |
|
|
NVTA
43
DELISTED
Invitae Corporation
NVTA
| $20.7M | 0.14% |
8,402,035
-1,471,453
| -15% | -$3.62M |
|
44
Biomea Fusion
BMEA
$114M
| $20.6M | 0.13% |
2,104,559
| – | – |
|
|
BCYC
45
Bicycle Therapeutics
BCYC
$492M
| $19.6M | 0.13% |
+843,814
| New | +$19.6M |
|
46
Ultragenyx Pharmaceutical
RARE
$3.04B
| $19.5M | 0.13% |
470,974
| – | – |
|
47
Instil Bio
TIL
$196M
| $18.8M | 0.12% |
194,685
| – | – |
|
48
Veru
VERU
$48.5M
| $18.5M | 0.12% |
+160,958
| New | +$18.5M |
|
49
Relmada Therapeutics
RLMD
$48.8M
| $18.3M | 0.12% |
495,113
| – | – |
|
50
Alkermes
ALKS
$4.95B
| $18.2M | 0.12% |
815,016
-684,984
| -46% | -$15.3M |
|